1. Pink Sheet
  2. >>Geography
  3. >>Europe

Coronavirus Update: Supercomputing, Regulatory Flexibilities & Coordinating Supply Strategies

 
• By Ian Schofield

In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.

Covid19_World_Map
The pandemic is driving global change in regulation and research priorities • Source: Shutterstock

The emergency use of (hydroxy)chloroquine, enlisting supercomputer power, relaxing the rules on coordinated supply strategies, and harmonizing COVID-19 reporting terms at global level – these are just some of the many avenues regulators and companies have been taking over the past week or so as the pandemic changes much of what we thought we knew about drug regulation.

There has been much pandemic-related activity in the EU, where the European Medicines Agency says it has had held discussions with developers of around 40 potential treatments and a dozen vaccines against the coronavirus, noting that two vaccines have already entered Phase I clinical trials

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Few Takers For EMA’s OPEN Pathway Prompts Rethink

 
• By Vibha Sharma

While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 
• By Eliza Slawther

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.